Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


First Filers Should Become Authorized Generics, Barr Argues

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO Downey cites Actiq as example of “rational” resolution to patent litigation.

You may also be interested in...

Cephalon And Barr Reach Patent Settlements For Provigil, Actiq

Barr could gain up to two months of exclusivity for its Actiq generic.

Shire Settles Adderall XR Patent Case With Impax, But Remains At Impasse With Barr

If a generic amphetamine extended-release launches before 2010, Impax will sell Shire’s authorized generic.

Teva Launches Generic Allegra Tablets Despite Patent Litigation

Marketing agreement between Barr, which is waiving its exclusivity, and Teva would allow the companies to share the litigation hazard of the "at risk" launch.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts